A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dose of IBI3002 in Patients With Atopic Dermatitis - a Randomized, Double-Blind, Placebo-Controlled Study
Latest Information Update: 20 Jun 2025
At a glance
- Drugs IBI 3002 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
Most Recent Events
- 20 Jun 2025 New trial record